Cancer and blood concentrations of the comutagen harmane in essential tremor

Elan D. Louis, Kathryn M. Pellegrino, Pam Factor-Litvak, Eileen Rios, Wendy Jiang, Claire Henchcliffe, Wei Zheng

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Blood concentrations of harmane, a tremor-producing neurotoxin, are elevated in essential tremor (ET). Harmane is also a comutagen. Using a case-control design, we compared the prevalence of cancer in ET cases vs. controls, and determined whether blood harmane concentrations are elevated among ET cases with cancer. 66/267 (24.7%) ET cases vs. 55/331 (16.6%) controls had cancer (adjusted OR 1.52, 95% CI 1.01-2.30, P = 0.04). Among specific cancer types, colon cancer was more prevalent in ET cases than controls (2.6% vs. 0.6%, P = 0.04). Log blood harmane concentration was higher in ET cases vs. controls (P = 0.02) and in participants with vs. without cancer (P = 0.02). Log blood harmane concentration was highest in ET cases with cancer when compared with other groups (P = 0.009). These links between cancer and ET and between high blood harmane and cancer in ET deserve further study.

Original languageEnglish (US)
Pages (from-to)1747-1751
Number of pages5
JournalMovement Disorders
Volume23
Issue number12
DOIs
StatePublished - Sep 15 2008
Externally publishedYes

Keywords

  • Cancer
  • Epidemiology
  • Essential tremor
  • Harmane
  • Toxin

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Cancer and blood concentrations of the comutagen harmane in essential tremor'. Together they form a unique fingerprint.

  • Cite this

    Louis, E. D., Pellegrino, K. M., Factor-Litvak, P., Rios, E., Jiang, W., Henchcliffe, C., & Zheng, W. (2008). Cancer and blood concentrations of the comutagen harmane in essential tremor. Movement Disorders, 23(12), 1747-1751. https://doi.org/10.1002/mds.22084